Table 1 Comparison of the clinical and pathological characteristics between non-adjuvant and adjuvant groups before and after PSM
Characteristics | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Non-adjuvant | Adjuvant | P | Non-adjuvant | Adjuvant | P | |
Age |  |  | < 0.001 |  |  | 1.000 |
< 65 | 55 (37.2%) | 36 (66.7%) |  | 35 (64.8%) | 36 (66.7%) |  |
≥ 65 | 93 (62.8%) | 18 (33.3%) |  | 19 (35.2%) | 18 (33.3%) |  |
Gender | Â | Â | 0.401 | Â | Â | 1.000 |
Female | 11 (7.43%) | 6 (11.1%) | Â | 5 (9.26%) | 6 (11.1%) | Â |
Male | 137 (92.6%) | 48 (88.9%) | Â | 49 (90.7%) | 48 (88.9%) | Â |
BMI | Â | Â | 0.924 | Â | Â | 1.000 |
Normal weight | 104 (70.3%) | 39 (72.2%) | Â | 39 (72.2%) | 39 (72.2%) | Â |
Under/Over weight | 44 (29.7%) | 15 (27.8%) | Â | 15 (27.8%) | 15 (27.8%) | Â |
Smoking History | Â | Â | 0.087 | Â | Â | 0.540 |
Never smoker | 35 (23.6%) | 20 (37.0%) | Â | 16 (29.6%) | 20 (37.0%) | Â |
Smoker or ex-smoker | 113 (76.4%) | 34 (63.0%) | Â | 38 (70.4%) | 34 (63.0%) | Â |
Pre-CT Tumor Size | Â | Â | 0.851 | Â | Â | 1.000 |
< 50 | 89 (60.1%) | 31 (57.4%) |  | 30 (55.6%) | 31 (57.4%) |  |
≥ 50 | 59 (39.9%) | 23 (42.6%) |  | 24 (44.4%) | 23 (42.6%) |  |
Clinical Stage | Â | Â | 0.652 | Â | Â | 0.837 |
I | 9 (6.08%) | 5 (9.26%) | Â | 4 (7.41%) | 5 (9.26%) | Â |
II | 52 (35.1%) | 20 (37.0%) | Â | 18 (33.3%) | 20 (37.0%) | Â |
III | 87 (58.8%) | 29 (53.7%) | Â | 32 (59.3%) | 29 (53.7%) | Â |
Tumor Location | Â | Â | 0.935 | Â | Â | 0.984 |
LLL | 27 (18.2%) | 12 (22.2%) | Â | 10 (18.5%) | 12 (22.2%) | Â |
LUL | 38 (25.7%) | 13 (24.1%) | Â | 13 (24.1%) | 13 (24.1%) | Â |
RLL | 38 (25.7%) | 12 (22.2%) | Â | 12 (22.2%) | 12 (22.2%) | Â |
RML | 5 (3.38%) | 1 (1.85%) | Â | 2 (3.70%) | 1 (1.85%) | Â |
RUL | 40 (27.0%) | 16 (29.6%) | Â | 17 (31.5%) | 16 (29.6%) | Â |
Histological Type | Â | Â | 0.384 | Â | Â | 0.804 |
LUAD | 35 (23.6%) | 9 (16.7%) | Â | 11 (20.4%) | 9 (16.7%) | Â |
LUSC | 113 (76.4%) | 45 (83.3%) | Â | 43 (79.6%) | 45 (83.3%) | Â |
pCR | Â | Â | 1.000 | Â | Â | 0.685 |
No | 94 (63.5%) | 34 (63.0%) | Â | 37 (68.5%) | 34 (63.0%) | Â |
Yes | 54 (36.5%) | 20 (37.0%) | Â | 17 (31.5%) | 20 (37.0%) | Â |
Neoadjuvant Cycles | Â | Â | 0.004 | Â | Â | 0.711 |
2 | 97 (65.5%) | 23 (42.6%) | Â | 23 (42.6%) | 23 (42.6%) | Â |
3 | 30 (20.3%) | 23 (42.6%) | Â | 20 (37.0%) | 23 (42.6%) | Â |
4 | 21 (14.2%) | 8 (14.8%) | Â | 11 (20.4%) | 8 (14.8%) | Â |